Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model

• Type of Material: Article
• Authors: Hayat Caidi, Centers for Disease Control and Prevention; Congrong Miao, Centers for Disease Control and Prevention; Natalie J. Thornburg, Centers for Disease Control and Prevention; Ralph A. Tripp, University of Georgia; Larry Anderson, Emory University; Lia M. Haynes, Centers for Disease Control and Prevention
• Language: English
• Date: 2018-06-01
• Publisher: Elsevier Science B.V.
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2018 Published by Elsevier B.V.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.antiviral.2018.04.014
• Title of Journal or Parent Work: Antiviral Research
• Volume: 154
• Start Page: 149
• End Page: 157
• Grant/Funding Information: The funding was supported by a grant from Trellis Biosciences through the CDC Foundation.
• Keywords: Infants; Infection; Monoclonal antibody; Virus; RSV; Prophylaxis; Challenges; CX3CR1; G protein; Pathogenesis; Prevention; G Glycoprotein; Life Sciences & Biomedicine; Virology; Palivizumab; Science & Technology; Mice; G-Protein; Pharmacology & Pharmacy; CX3C; Responses
• Research Categories: Biology, Virology; Health Sciences, Immunology; Health Sciences, Pharmacology

Abstract

RSV continues to be a high priority for vaccine and antiviral drug development. Unfortunately, no safe and effective RSV vaccine is available and treatment options are limited. Over the past decade, several studies have focused on the role of RSV G protein on viral entry, viral neutralization, and RSV-mediated pathology. Anti-G murine monoclonal antibody (mAb) 131-2G treatment has been previously shown to reduce weight loss, bronchoalveolar lavage (BAL) cell number, airway reactivity, and Th2-type cytokine production in RSV-infected mice more rapidly than a commercial humanized monoclonal antibody (mAb) against RSV F protein (Palivizumab). In this study, we have tested two human anti-RSV G mAbs, 2B11 and 3D3, by both prophylactic and therapeutic treatment for RSV in the BALB/c mouse model. Both anti-G mAbs reduced viral load, leukocyte infiltration and IFN-γ and IL-4 expression in cell-free BAL supernatants emphasizing the potential of anti-G mAbs as anti-inflammatory and antiviral strategies.